Biomarkers for cervical cancer screening

• Verfasst von: Knebel Doeberitz, Magnus von [VerfasserIn]
• Verfasst von: Reuschenbach, Miriam [VerfasserIn]
• Verfasst von: Schmidt, Dietmar [VerfasserIn]
• Titel: Biomarkers for cervical cancer screening
• Titelzusatz: the role of p16INK4a to highlight transforming HPV infections
• Verf.angabe: Magnus von Knebel Doeberitz, Miriam Reuschenbach, Dietmar Schmidt, Christine Bergeron
• Umfang: 15 S.
• Fussnoten: Gesehen am 23.05.2018
• Titel Quelle: Enthalten in: Expert review of proteomics
• Jahr Quelle: 2012
• Band/Heft Quelle: 9(2012), 2, S. 149-163
• ISSN Quelle: 1744-8387
• DOI: doi:10.1586/epr.12.13
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1575448475

Abstract

Biomarkers indicating the initiation of neoplastic transformation processes in human papillomavirus (HPV)-infected epithelial cells are moving into the focus of cancer prevention research, particularly for anogenital cancer, including cancer of the uterine cervix. Based on the in-depth understanding of the molecular events leading to neoplastic transformation of HPV-infected human cells, the cyclin-dependent kinase inhibitor p16INK4a turned out to be substantially overexpressed in virtually all HPV-transformed cells. This finding opened novel avenues in diagnostic histopathology to substantially improve the diagnostic accuracy of cervical cancer and its precursor lesions. Furthermore, it provides a novel technical platform to substantially improve the accuracy of cytology-based cancer early-detection programs. Here, we review the molecular background and the current evidence for the clinical utility of the p16INK4a biomarker for HPV-related cancers, and cervical cancer prevention in particular.